32.12
Schlusskurs vom Vortag:
$31.77
Offen:
$32
24-Stunden-Volumen:
2.36M
Relative Volume:
1.64
Marktkapitalisierung:
$20.61B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
21.41
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+11.37%
1M Leistung:
+24.06%
6M Leistung:
+70.67%
1J Leistung:
+35.58%
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GMAB
Genmab Adr
|
32.12 | 19.56B | 2.62B | 966.70M | 1.09B | 1.5004 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.85 | 103.64B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.99 | 60.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
ARGX
Argen X Se Adr
|
791.59 | 46.96B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
345.17 | 36.81B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
2023-12-06 | Hochstufung | UBS | Neutral → Buy |
2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-08-24 | Eingeleitet | BTIG Research | Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-31 | Eingeleitet | UBS | Neutral |
2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
2022-05-02 | Eingeleitet | Cowen | Market Perform |
2022-03-16 | Hochstufung | UBS | Neutral → Buy |
2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2021-12-01 | Eingeleitet | Berenberg | Sell |
2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
2020-01-13 | Eingeleitet | SunTrust | Buy |
2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-08-12 | Eingeleitet | Guggenheim | Buy |
2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World
TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga
European Stocks Higher to Kick Off the Week - TradingView
Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World
Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se
Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World
Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat
Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat
Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World
IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):